A public health timeline to prepare for COVID-19 vaccines in Canada

被引:0
|
作者
Noni E. MacDonald
Jeannette Comeau
Eve Dubé
Lucie Bucci
Janice E. Graham
机构
[1] Dalhousie University,Department of Pediatrics
[2] IWK Health Centre,undefined
[3] Institut National de Santé Publique du Québec and Université Laval,undefined
[4] Québec,undefined
[5] Immunize Canada,undefined
[6] Canadian Public Health Association,undefined
来源
关键词
COVID-19 vaccines; COVID-19 immunization; Public health; Pandemic control; Communication; Vaccins contre la COVID-19; Vaccination contre la COVID-19; Santé publique; Contrôle de la pandémie; Communication;
D O I
暂无
中图分类号
学科分类号
摘要
For control of COVID-19, community immunity is required, necessitating widespread immunization. COVID-19 vaccines are coming to Canada, with the government announcing in August 2020 agreements with four different companies for their COVID-19 vaccine if their trials are successful. Never before has public health had to rapidly develop a vaccine introduction program for multiple new but differing vaccines with the added pressure that the program is needed across all ages and in all Canadian communities and there is high probability of not enough vaccine to go around at the start. Traditional public health vaccine introduction planning will need to be both accelerated and more comprehensive to ensure optimal uptake across the country. This overview highlights a number of points for consideration by public health in their planning for COVID-19 vaccines before these COVID-19 vaccines are available, once they are available, once supplies are plentiful, and throughout the vaccine program. Targeted and tailored communications are key elements needed to reach and positively influence diverse communities, regions, ages, languages, education levels and lived experiences.
引用
收藏
页码:945 / 952
页数:7
相关论文
共 50 条
  • [41] COVID-19 Vaccines
    不详
    [J]. US PHARMACIST, 2021, 46 (02)
  • [42] Vaccines for COVID-19
    Tregoning, J. S.
    Brown, E. S.
    Cheeseman, H. M.
    Flight, K. E.
    Higham, S. L.
    Lemm, N-M
    Pierce, B. F.
    Stirling, D. C.
    Wang, Z.
    Pollock, K. M.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2020, 202 (02): : 162 - 192
  • [43] COVID-19 vaccines
    Demirdover, Cenk
    [J]. TURKISH JOURNAL OF PLASTIC SURGERY, 2021, 29 (01) : 1 - 3
  • [44] COVID-19 Vaccines
    Hahn, William O.
    Wiley, Zanthia
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2022, 36 (02) : 481 - 494
  • [45] COVID-19 vaccines
    Ndwandwe, Duduzile
    Wiysonge, Charles S.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2021, 71 : 111 - 116
  • [46] COVID-19 Vaccines
    Afzal, Saira
    Nasir, Mehreen
    [J]. ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2021, 27 (01): : 1 - 3
  • [47] CANADA AND COVID-19: MAJOR PUBLIC LAW ISSUES
    Guenette, Dave
    Mathieu, Felix
    [J]. REVISTA CATALANA DE DRET PUBLIC, 2020, : 225 - 233
  • [48] Health equity and vulnerability in the access to COVID-19 vaccines
    de Castro-Nunes, Paula
    Ribeiro, Gizele da Rocha
    [J]. REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2022, 46
  • [49] Vaccines against COVID-19, a challenge in Global Health
    Guillermo Toapanta-Yugcha, Ivan
    Jose Rodrigues-Flores, Maria
    Celena Rea-Chusin, Nataly
    David Villacis-Benavides, Jairo
    [J]. INVESTIGACION CLINICA, 2021, 62 : 259 - 267
  • [50] A public health mission in Canada in response to the coronavirus disease 2019 (COVID-19) pandemic
    Marie Lavoie
    [J]. Global Health Journal, 2022, (04) : 231 - 236